-- Spanish Stocks: Vocento, Indra Sistemas, La Seda de Barcelona Are Active
-- B y   P a u l   T o b i n   a n d   M a n u e l   B a i g o r r i
-- 2010-11-12T11:21:19Z
-- http://www.bloomberg.com/news/2010-11-12/spanish-stocks-vocento-indra-sistemas-la-seda-de-barcelona-are-active.html
Spain’s  IBEX 35 Index  advanced after
two days of losses, gaining 52.6, or 0.5 percent, to 10,202.1 as
of 11:54 a.m. in Madrid. The measure has lost 2.2 percent this
week.  The following were among the most active stocks in the
Spanish market. Symbols are in parentheses after company names.  Banco Bilbao Vizcaya Argentaria SA  (BBVA SM) rose 2.6
percent to 8.30 euros, snapping two days of losses. Spain’s
second-biggest bank was raised to “neutral” from “sell” at
UBS AG.  Banco Popular Espanol SA  (POP SM) increased 3.6 percent to
4.34 euros, breaking five days of losses. Spanish banks reduced
in October their European Central Bank borrowings to 67.9
billion euros from 97.7 billion euros in September, the Bank of
Spain said today.  Indra Sistemas SA  (IDR SM) dropped for a second day, losing
3.3 percent to 13.30 euros. Spain’s largest computer-services
company said nine-month profit dropped 5 percent to 143.4
million euros ($195.5 million) as sales in Spain decreased. The
company forecast a 2 percent increase in full-year sales, at the
low end of a range of 2 percent to 4 percent that it set in
January.  La Seda de Barcelona SA  (SED SM) climbed 1.5 percent to 7
euro cents, the first gain in three days. Europe’s largest maker
of polyethylene terephthalate, a type of polyester, said its
nine-month net loss narrowed to 29.5 million euros from a loss
of 382.4 million euros a year earlier.  Vocento SA  (VOC SM) fell for a fifth day, losing 2.4
percent to 3.52 euros. Spain’s largest newspaper publisher
posted a nine-month loss of 12.3 million euros, compared with a
profit of 47.2 million euros a year earlier. Sales fell 4.1
percent to 531 million euros, it said.  Zeltia SA  (ZEL SM) slipped for a third day, losing 2.3
percent to 2.96 euros. Centocor Ortho Biotech Products LP, the
Johnson & Johnson unit that owns the marketing rights for
Yondelis outside Europe and Japan, withdrew a request for
approval to sell the drug in Australia and plans to present more
data to regulators in that country, according to a regulatory
filing from Zeltia SA, the developer of Yondelis. Centocor has
won approval to sell Yondelis as a treatment for ovarian cancer
in Colombia, Zeltia said.  To contact the reporter on this story:
Paul Tobin in Madrid at 
 ptobin@bloomberg.net ;
Manuel Baigorri in Madrid at 
 mbaigorri@bloomberg.net .  To contact the editor responsible for this story:
David Merritt at 
 dmerritt1@bloomberg.net . 